Literature DB >> 10903406

Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance.

D S Manoach1, R L Gollub, E S Benson, M M Searl, D C Goff, E Halpern, C B Saper, S L Rauch.   

Abstract

BACKGROUND: Working memory (WM) deficits in schizophrenia have been associated with dorsolateral prefrontal cortex (DLPFC) dysfunction in neuroimaging studies. We previously found increased DLPFC activation in schizophrenic versus normal subjects during WM performance (Manoach et al 1999b). We now have investigated whether schizophrenic subjects recruit different brain regions, particularly the basal ganglia and thalamus, components of frontostriatal circuitry thought to mediate WM.
METHODS: We examined regional brain activation in nine normal and nine schizophrenic subjects during WM performance using functional magnetic resonance imaging. Subjects performed a modified version of the Sternberg Item Recognition Paradigm that included a monetary reward for correct responses. We compared high and low WM load conditions to each other and to a non-WM baseline condition. We examined activation in both individual subjects and averaged group data.
RESULTS: Relative to normal subjects, schizophrenic subjects exhibited deficient WM performance, at least an equal magnitude of right DLPFC activation, significantly greater left DLPFC activation, and increased spatial heterogeneity of DLPFC activation. Furthermore, only the schizophrenic group activated the basal ganglia and thalamus, even when matched for task performance with the normal group.
CONCLUSIONS: Aberrant WM performance and brain activation in schizophrenia may reflect dysfunction of frontostriatal circuitry that subserves WM. Future studies will elucidate the contribution of the anatomical components of this circuitry to WM deficits.

Entities:  

Mesh:

Year:  2000        PMID: 10903406     DOI: 10.1016/s0006-3223(00)00227-4

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  165 in total

1.  Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors.

Authors:  Claude Sebban; Brigitte Tesolin-Decros; Jorge Ciprian-Ollivier; Laurent Perret; Michael Spedding
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

2.  Encoding novel face-name associations: a functional MRI study.

Authors:  R A Sperling; J F Bates; A J Cocchiarella; D L Schacter; B R Rosen; M S Albert
Journal:  Hum Brain Mapp       Date:  2001-11       Impact factor: 5.038

3.  Prefrontal dopamine D1 receptors and working memory in schizophrenia.

Authors:  Anissa Abi-Dargham; Osama Mawlawi; Ilise Lombardo; Roberto Gil; Diana Martinez; Yiyun Huang; Dah-Ren Hwang; John Keilp; Lisa Kochan; Ronald Van Heertum; Jack M Gorman; Marc Laruelle
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

4.  Multi-site characterization of an fMRI working memory paradigm: reliability of activation indices.

Authors:  Anastasia Yendiki; Douglas N Greve; Stuart Wallace; Mark Vangel; Jeremy Bockholt; Bryon A Mueller; Vince Magnotta; Nancy Andreasen; Dara S Manoach; Randy L Gollub
Journal:  Neuroimage       Date:  2010-05-05       Impact factor: 6.556

5.  MRI study of caudate nucleus volume and its cognitive correlates in neuroleptic-naive patients with schizotypal personality disorder.

Authors:  James J Levitt; Robert W McCarley; Chandlee C Dickey; Martina M Voglmaier; Margaret A Niznikiewicz; Larry J Seidman; Yoshio Hirayasu; Aleksandra A Ciszewski; Ron Kikinis; Ferenc A Jolesz; Martha E Shenton
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

Review 6.  Insights and treatment options for psychiatric disorders guided by functional MRI.

Authors:  Tonmoy Sharma
Journal:  J Clin Invest       Date:  2003-07       Impact factor: 14.808

Review 7.  Functional magnetic resonance imaging: emerging clinical applications.

Authors:  Heather A Wishart; Andrew J Saykin; Thomas W McAllister
Journal:  Curr Psychiatry Rep       Date:  2002-10       Impact factor: 5.285

Review 8.  [Genetic and pharmacological effects on prefrontal cortical function in schizophrenia].

Authors:  Andreas Heinz; Dieter F Braus; Berenice Romero; Jürgen Gallinat; Imke Puls; Georg Juckel; Daniel R Weinberger
Journal:  Nervenarzt       Date:  2004-09       Impact factor: 1.214

9.  White matter abnormalities in 22q11.2 deletion syndrome: preliminary associations with the Nogo-66 receptor gene and symptoms of psychosis.

Authors:  Matthew D Perlstein; Moeed R Chohan; Ioana L Coman; Kevin M Antshel; Wanda P Fremont; Matthew H Gnirke; Zora Kikinis; Frank A Middleton; Petya D Radoeva; Martha E Shenton; Wendy R Kates
Journal:  Schizophr Res       Date:  2013-12-08       Impact factor: 4.939

Review 10.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.